14.07.2016
Biotest AG DE0005227235
DGAP-News: Biotest AG: Former Biotest employee sentenced
DGAP-News: Biotest AG / Key word(s): Legal Matter
Biotest AG: Former Biotest employee sentenced
14.07.2016 / 17:46
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
Former Biotest employee sentenced
Dreieich, 14 July 2016. Today, the Landgericht Darmstadt (District Court
Darmstadt, Germany) sentenced a former Biotest representative for Russia to
imprisonment of 5 years and 9 months. According to the judgement of the
court, the former employee is guilty of complicity in fraud and tax evasion
in the years 2007-2011. Her husband was sentenced to imprisonment of 4
years and 6 months. The sentence is not yet final. An appeal to the
Bundesgerichtshof (German Federal Court of Justice) is possible. The
company had dismissed the former employee in 2013. Biotest AG is not a
party in these proceedings. The sentence pertains neither to Biotest AG nor
to any officials of Biotest. The company will await the written grounds for
the verdict and evaluate possible next steps against the accused. Biotest
had restructured its sales and distribution in Russia in January 2013. The
company has since been cooperating with a big German pharmaceutical
company.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,300
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: [email protected]
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
Munich, Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
---------------------------------------------------------------------------
14.07.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [email protected]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg,
Stuttgart
End of News DGAP News Service
---------------------------------------------------------------------------
482597 14.07.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biotest AG ISIN: DE0005227235 können Sie bei EQS abrufen
Gesundheit , 522723 , BIO3 , XETR:BIO3